Testing effectiveness (Phase 2)UnknownNCT04248387What this trial is testingToripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type MelanomaWho this might be right forMelanoma Stage IIIB-IV Fudan University 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT02231775What this trial is testingDabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 MutationWho this might be right forStage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7 M.D. Anderson Cancer Center 58
Testing effectiveness (Phase 2)Study completedNCT04133948What this trial is testingMulticenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary MelanomaWho this might be right forMalignant Melanoma Stage III The Netherlands Cancer Institute 44
Testing effectiveness (Phase 2)Ended earlyNCT02303951What this trial is testingNeoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VCWho this might be right forMalignant Melanoma University Hospital Tuebingen 47
Not applicableStudy completedNCT07091695What this trial is testingReal-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+IpilimumabWho this might be right forMelanoma Bristol-Myers Squibb 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT05081609What this trial is testingInvestigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor MalignanciesWho this might be right forAdvanced Solid TumorLocally Advanced Solid TumorMetastatic Solid Tumor+10 more Ascendis Pharma Oncology Division A/S 320
Testing effectiveness (Phase 2)Active Not RecruitingNCT05187884What this trial is testingNeoadjuvant/Adjuvant Trial of Darovasertib in Ocular MelanomaWho this might be right forOcular Melanoma St Vincent's Hospital, Sydney 15
Early research (Phase 1)Study completedNCT02339324What this trial is testingNeoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2bWho this might be right forMelanoma Yana Najjar 31
Testing effectiveness (Phase 2)Study completedNCT01341158What this trial is testingNAM-Trial: Multiferon in Malignant MelanomaWho this might be right forLocoregional Metastases in Malignant Melanoma Stages IIIB/C University Hospital Tuebingen 42
Testing effectiveness (Phase 2)Study completedNCT00525031What this trial is testingTemozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma PatientsWho this might be right forMelanoma M.D. Anderson Cancer Center 55
Not applicableStudy completedNCT00596362What this trial is testingTreatment With Intravitreal Avastin for Large Uveal MelanomasWho this might be right forUveal Melanoma Memorial Sloan Kettering Cancer Center 1
Testing effectiveness (Phase 2)UnknownNCT04622566What this trial is testingLenvatinib and Pembrolizumab in Resectable Mucosal MelanomaWho this might be right forMucosal MelanomaNeoadjuvant Treatment Peking University Cancer Hospital & Institute 26
Large-scale testing (Phase 3)Active Not RecruitingNCT04949113What this trial is testingNeoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III MelanomaWho this might be right forMalignant Melanoma Stage III The Netherlands Cancer Institute 423
Early research (Phase 1)Active Not RecruitingNCT06014086What this trial is testingIntratumoral PH-762 for Cutaneous CarcinomaWho this might be right forSquamous Cell Carcinoma of the SkinMalignant Melanoma of SkinMerkel Cell Carcinoma of Skin Phio Pharmaceuticals Inc. 30
Testing effectiveness (Phase 2)WithdrawnNCT04007588What this trial is testingA Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV MelanomaWho this might be right forMelanoma Stage IIIMelanoma Stage IV Dana-Farber Cancer Institute
Testing effectiveness (Phase 2)Ended earlyNCT04310397What this trial is testingDabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D MelanomaWho this might be right forPathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8 M.D. Anderson Cancer Center 4
Very early researchStudy completedNCT00972933What this trial is testingImmunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for MelanomaWho this might be right forMelanoma Diwakar Davar 59
Testing effectiveness (Phase 2)WithdrawnNCT03005639What this trial is testingML29255 Neoadjuvant Vemurafenib and Cobimetinib MelanomaWho this might be right forStage IIIB-C Melanoma Inova Health Care Services
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07517653What this trial is testingNeoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal MelanomaWho this might be right forMelanoma Shanghai Zhongshan Hospital 70
Testing effectiveness (Phase 2)Looking for participantsNCT06295159What this trial is testingNeoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced MelanomaWho this might be right forMelanoma Stage IIIMelanoma Stage IVAdvanced Melanoma+1 more H. Lee Moffitt Cancer Center and Research Institute 90